Effect of Venous Thrombotic Events on Overall Survival in Multiple Myeloma: Analysis of Thrombotic Events Occurring in E4A03A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma, a Trial Coordinated by the Eastern Cooperative Oncology Group (ECOG).

被引：0
|
作者：
Jacobus, Susanna [1 ]
Kumar, Shaji [2 ]
Callander, Natalie Scott [3 ]
Abonour, Rafat [4 ]
Fonseca, Rafael [5 ]
Siegel, David [6 ]
Greipp, Philip [2 ]
Rajkumar, S. Vincent [2 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Mayo Clin, Rochester, MN USA
[3] Univ Wisconsin, Madison, WI USA
[4] Indiana Univ Canc, Indianapolis, IN USA
[5] Mayo Clin, Scottsdale, AZ USA
[6] Hackensack Univ, Med Ctr, Hackensack, NJ USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：613 / 614
页数：2
相关论文
共 50 条
  • [1] A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the eastern cooperative oncology group
    Rajkumar, S. Vincent
    Jacobus, Susanna
    Callander, Natalie
    Fonseca, Rafael
    Vesole, David
    Williams, Michael
    Abonour, Rafat
    Siegel, David
    Greipp, Philip
    BLOOD, 2007, 110 (11) : 31A - 31A
  • [2] Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern Cooperative Oncology Group
    Rajkumar, S. V.
    Jacobus, S.
    Callander, N.
    Fonseca, R.
    Vesole, D.
    Williams, M.
    Abonour, R.
    Siegel, D.
    Greipp, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group: Analysis of response, survival, and outcome wi
    Rajkumar, S. V.
    Jacobus, S.
    Callander, N.
    Fonseca, R.
    Vesole, D.
    Williams, M. V.
    Abonour, R.
    Siegel, D. S.
    Katz, M.
    Greipp, P. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] A randomized phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4AO3): A trial coordinated by the Eastern Cooperative Oncology Group.
    Rajkumar, S. Vincent
    Jacobus, Susanna
    Callander, Natalie
    Fonseca, Rafael
    Vesole, David
    Greipp, Philip
    BLOOD, 2006, 108 (11) : 239A - 240A
  • [5] Phase III trial of thalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (07): : 452 - 453
  • [6] OUTCOME OF ELDERLY PATIENTS 70 YEARS AND OLDER WITH NEWLY DIAGNOSED MYELOMA IN THE ECOG RANDOMIZED TRIAL OF LENALIDOMIDE/HIGH-DOSE DEXAMETHASONE (RD) VERSUS LENALIDOMIDE/LOW-DOSE DEXAMETHASONE (RD)
    Jacobus, S.
    Callander, N.
    Siegel, D.
    Abonour, R.
    David, D.
    Fonseca, R.
    Williams, M.
    Katz, M.
    Greipp, P.
    Rajkumar, V.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 149 - 149
  • [7] Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
    Rajkumar, S. Vincent
    Jacobus, Susanna
    Callander, Natalie S.
    Fonseca, Rafael
    Vesole, David H.
    Williams, Michael E.
    Abonour, Rafat
    Siegel, David S.
    Katz, Michael
    Greipp, Philip R.
    LANCET ONCOLOGY, 2010, 11 (01): : 29 - 37
  • [8] Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone: Results of the phase III E4A03 trial for newly diagnosed patients
    Muneer, Sabeeha
    Cunningham, Sonia
    CLINICAL LYMPHOMA & MYELOMA, 2008, 8 (01): : 17 - 18
  • [9] Effect of thrombotic events on overall survival in patients with newly diagnosed myeloma: Analysis from a randomized phase III trial of thalidomide plus dexamethasone versus dexamethasone in newly diagnosed multiple myeloma (E1A00)
    Kumar, Shaji
    Zhang, Lijun
    Greipp, Philip R.
    Rajkumar, S. Vincent
    BLOOD, 2007, 110 (11) : 803A - 803A
  • [10] Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study
    Sborov, Douglas W.
    Baljevic, Muhamed
    Reeves, Brandi
    Laubach, Jacob
    Efebera, Yvonne A.
    Rodriguez, Cesar
    Costa, Luciano J.
    Chari, Ajai
    Silbermann, Rebecca
    Holstein, Sarah A.
    Anderson, Larry D., Jr.
    Kaufman, Jonathan L.
    Shah, Nina
    Pei, Huiling
    Patel, Sharmila
    Cortoos, Annelore
    Bartlett, J. Blake
    Vermeulen, Jessica
    Lin, Thomas S.
    Voorhees, Peter M.
    Richardson, Paul G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 199 (03) : 355 - 365
12345